We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.15%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.05B
AUM Growth
-$412M
(-17%)
Cap. Flow
-$506M
Cap. Flow
% of AUM
-24.65%
Top 10 Holdings %
Top 10 Hldgs %
62.87%
Holding
41
New
10
Increased
7
Reduced
9
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$69.8M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$33.7M |
| 3 |
Biogen
BIIB
|
+$26.4M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$23.3M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LivaNova
LIVN
|
+$58.8M |
| 2 |
Perrigo
PRGO
|
+$53.7M |
| 3 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$49.5M |
| 4 |
Abbott
ABT
|
+$44.4M |
| 5 |
Alkermes
ALKS
|
+$42.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| $242M | 11.77% |
1,000,000
-2,000,000
| -67% | -$479M |
|
2
Teva Pharmaceuticals
TEVA
$41.2B
| $175M | 8.52% |
5,266,450
+50,000
| +1% | +$1.55M |
|
3
Viatris
VTRS
$20.7B
| $165M | 8.02% |
4,245,889
+100,000
| +2% | +$3.84M |
|
4
CALL
Gilead Sciences
GILD
$163B
| $142M | 6.89% |
2,000,000
+1,000,000
| +100% | +$66.5M |
|
|
5
Gilead Sciences
GILD
$163B
| $142M | 6.89% |
2,000,000
+100,000
| +5% | +$6.65M |
|
6
Nektar Therapeutics
NKTR
$2.41B
| $105M | 5.09% |
356,667
-3,333
| -0.9% | -$963K |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $85.1M | 4.14% |
350,000
-85,750
| -20% | -$20.1M |
|
|
GHDX
8
DELISTED
Genomic Health, Inc.
GHDX
| $80M | 3.9% |
2,458,100
| – | – |
|
9
Brookdale Senior Living
BKD
$3.49B
| $79.4M | 3.87% |
5,400,000
-100,000
| -2% | -$1.38M |
|
10
Myriad Genetics
MYGN
$507M
| $77.5M | 3.77% |
3,000,000
-1,325,000
| -31% | -$28.1M |
|
|
11
Tenet Healthcare
THC
$21.8B
| $77.4M | 3.77% |
+4,000,000
| New | +$69.8M |
|
|
SEM
12
DELISTED
Select Medical
SEM
| $76.8M | 3.74% |
9,280,000
| – | – |
|
|
BIVV
13
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $70.7M | 3.44% |
1,174,300
+74,300
| +7% | +$4.23M |
|
14
Orthofix Medical
OFIX
$477M
| $69.7M | 3.39% |
1,500,000
| – | – |
|
15
Vertex Pharmaceuticals
VRTX
$122B
| $45.1M | 2.2% |
350,000
-300,000
| -46% | -$36.1M |
|
16
Sarepta Therapeutics
SRPT
$1.64B
| $43.8M | 2.13% |
1,300,000
-50,000
| -4% | -$1.63M |
|
|
ENDP
17
DELISTED
Endo International plc
ENDP
| $39.9M | 1.94% |
3,574,000
-1,478,000
| -29% | -$17.4M |
|
|
ELGX
18
DELISTED
Endologix Inc
ELGX
| $36.5M | 1.77% |
750,000
+150,000
| +25% | +$8.83M |
|
|
19
CALL
Teva Pharmaceuticals
TEVA
$41.2B
| $33.2M | 1.62% |
+1,000,000
| New | +$31M |
|
|
AMAG
20
DELISTED
AMAG Pharmaceuticals
AMAG
| $31.3M | 1.52% |
+1,700,000
| New | +$33.7M |
|
21
Option Care Health
OPCH
$3.36B
| $27.6M | 1.35% |
2,545,000
| – | – |
|
|
22
Biogen
BIIB
$30.7B
| $27.1M | 1.32% |
+100,000
| New | +$26.4M |
|
|
ELOS
23
DELISTED
Syneron Medical Ltd
ELOS
| $25.7M | 1.25% |
2,347,593
| – | – |
|
|
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
| $24.3M | 1.18% |
+200,000
| New | +$23.3M |
|
|
SIOX
25
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $23.2M | 1.13% |
+125,000
| New | +$21.9M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, Camber Capital Management held 41 positions worth $2.05B, down 17% from $2.47B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Camber Capital Management withdrew a net $506M in Q2 2017, closing 7 positions and reducing 9 holdings. Its most notable exit was LivaNova, an estimated $58.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 60% a quarter earlier.
Against the trend, Camber Capital Management opened a new position in Tenet Healthcare worth $77.4M.
- Camber Capital Management's largest Q2 2017 buy was Tenet Healthcare: 4,000,000 shares worth $77.4M.
- Camber Capital Management added most to Endologix Inc in Q2 2017, an estimated $8.83M increase.
- Camber Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $36.1M.
- Camber Capital Management fully exited LivaNova in Q2 2017, selling an estimated $58.8M.
- Camber Capital Management's ten largest holdings make up 63% of its $2.05B portfolio in Q2 2017.
- Camber Capital Management opened 10 new positions and closed 7 in Q2 2017.
- Camber Capital Management's portfolio value fell 17% quarter-over-quarter to $2.05B.
Based on Camber Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.